Compare Sanofi SA (SNY) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Vale SA — how do they compare? Sanofi SA trades at $43.64 (market cap $104.30B), while Vale SA trades at $14.47 (market cap $61.97B). The key difference: Sanofi SA is the larger of the two by market cap, and Vale SA pays the higher dividend (8.35%). Which is the better fit depends on your goals.
| SNY | VALE | |
|---|---|---|
Market Cap | $104.30B | $61.97B |
Sector | Health | Basic Materials |
52-Week High | $52.34 | $17.82 |
52-Week Low | $41.33 | $9.71 |
Enterprise Value | $124.19B | $78.22B |
Dividend Yield | 5.55% | 8.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
VALE trades at $14.49, down 2.72% with a bearish technical outlook. Recent earnings missed expectations for three consecutive quarters, with Q3 2026 results pending. The company maintains strong cash flow generation ($8.8B operating cash flow in 2025) and a 5.11% net margin, though profitability has declined from 2022 peaks. Analyst consensus is mixed with 38% Buy ratings and a $16.79 price target, representing 16% upside potential.
VALE offers value with reasonable valuations (P/E 28.6, P/B 1.6) and dividend yield, but faces headwinds from rising costs and earnings volatility. The stock's near-term trajectory depends on Q3 earnings delivery and copper segment execution. Key risks include commodity price sensitivity and operational challenges in base metals expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
